US Stock Market Moves: Zai Lab surges on October 23rd with positive Zoci lung cancer data and $250 million financing

Zai Lab Surges on October 23: Analysis

Keywords: Positive Zoci lung cancer data, $250 million financing

1. On October 23, Zai Lab announced the first global phase 1b data for Zoci (formerly known as ZL-1310) in combination with atezolizumab as a first-line treatment for extensive-stage small cell lung cancer: at the recommended phase 3 dose of 1.6 mg/kg, the confirmed objective response rate was 81.8% (27/33), and the estimated 6-month progression-free survival rate was 81.9% (n=33); among patients with at least 6 months of follow-up, the median follow-up was 10 months, with both median progression-free survival and median duration of response not yet reached; incidence of Zoci-related grade 3 or above adverse events was 9.1% (3/33); the global randomized phase 3 study is expected to start before the end of 2026.

2. On October 22, Eastern Time, the company entered into a securities purchase agreement with investors for a private placement of 11.34 million ADS at $22.04 per share, raising a total of approximately $250 million. After deducting expenses, the net proceeds were around $241.2 million, mainly used to support the continued global development of DLL3-targeted ADC Zoci. Participants included new and existing investors such as TCGX, abrdn World Healthcare Fund, Balyasny Asset Management, RA Capital Management, RTW Investments, and Wellington Management.

(Disclaimer: This content is generated by AI technology summarizing publicly available information and is for reference only. It does not constitute investment advice.)